|Bid||105.00 x 900|
|Ask||107.00 x 1000|
|Day's range||104.52 - 108.34|
|52-week range||100.39 - 147.43|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||75.76|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Zimmer Biomet (ZBH) gets FDA nod for the Identity Shoulder System to help surgeons perform anatomic, reverse and revision shoulder replacement with precision.
Zimmer (ZBH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zimmer Biomet's (ZBH) recently completed spin-off of the non-core dental and spine business is expected to prove strategic.